Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells

Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors

(2020) Giovanni Fucá et al.   CLINICAL CANCER RESEARCH

PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer

(2020) Brian Diskin et al.   NATURE IMMUNOLOGY

Development of CAR-T cell therapies for multiple myeloma

(2020) Nico Gagelmann et al.   LEUKEMIA

The adenosine pathway in immuno-oncology

(2020) Bertrand Allard et al.   Nature Reviews Clinical Oncology

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

(2020) Lukas F. Mager et al.   SCIENCE

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis

(2019) Emma J.M. Grigor et al.   TRANSFUSION MEDICINE REVIEWS

Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes

(2019) Magdalena Maria Dutsch-Wicherek et al.   Ginekologia Polska

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

(2019) Jun Ishihara et al.   Science Translational Medicine

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

(2019) Selena Vigano et al.   Frontiers in Immunology

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells

(2019) Beatris Mastelic-Gavillet et al.   Journal for ImmunoTherapy of Cancer

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models

(2018) Robert D. Leone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhancement of inosine-mediated A 2A R signaling through positive allosteric modulation

(2018) Ajith A. Welihinda et al.   CELLULAR SIGNALLING

Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment

(2018) Isabelle Meyts et al.   JOURNAL OF CLINICAL IMMUNOLOGY

CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction

(2018) Natnaree Siriwon et al.   Cancer Immunology Research

Targeting adenosine for cancer immunotherapy

(2018) Robert D. Leone et al.   Journal for ImmunoTherapy of Cancer

Harnessing albumin as a carrier for cancer therapies

(2018) Ella N. Hoogenboezem et al.   ADVANCED DRUG DELIVERY REVIEWS

Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms

(2018) Barbara Kutryb-Zajac et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reorganized Collagen in the Tumor Microenvironment of Gastric Cancer and Its Association with Prognosis

(2017) Zhi-Hua Zhou et al.   Journal of Cancer

The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias

(2016) Ajith A. Welihinda et al.   CELLULAR SIGNALLING

Immunosuppressive activities of adenosine in cancer

(2016) Bertrand Allard et al.   CURRENT OPINION IN PHARMACOLOGY

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization

(2016) K. Newick et al.   Cancer Immunology Research

Adenosine Deaminase Deficiency – More Than Just an Immunodeficiency

(2016) Kathryn V. Whitmore et al.   Frontiers in Immunology

CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

(2015) Martin Turcotte et al.   CANCER RESEARCH

CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression

(2015) María Rosa Bono et al.   FEBS LETTERS

A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy

(2015) Hui Liang et al.   JOURNAL OF CONTROLLED RELEASE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment

(2014) Gregory L Beatty et al.   OncoImmunology

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ENTPD1/CD39 is a promising therapeutic target in oncology

(2012) J Bastid et al.   ONCOGENE

The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

(2012) Akio Ohta et al.   Frontiers in Immunology

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity

(2011) Sebastian F. M. Häusler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression

(2011) Gennady G. Yegutkin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Extracellular adenosine triphosphate and adenosine in cancer

(2010) J Stagg et al.   ONCOGENE

Why are tumour blood vessels abnormal and why is it important to know?

(2009) J A Nagy et al.   BRITISH JOURNAL OF CANCER

Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function

(2008) Balázs Csóka et al.   FASEB JOURNAL

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

(2008) György Haskó et al.   NATURE REVIEWS DRUG DISCOVERY

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE